Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating remibrutinib, an oral medication, in a Phase III clinical trial involving adolescents and adults aged 12 to 65 with IgE-mediated allergies to peanut, cows milk cooked and uncooked, or hens egg cooked and uncooked. The study compares remibrutinib to a placebo to assess its safety and effectiveness in managing these food allergies. Participants are divided into four sub-studies based on their specific allergy peanut, milk, egg, or a combination of these allergens. During the initial treatment period, participants receive either remibrutinib or placebo for up to 24 weeks in the first three sub-studies, and up to 4 weeks in the fourth sub-study. After this, all participants enter an open-label phase where they receive remibrutinib until Week 52. Following this period, eligible participants can join a separate open-label post-trial study to evaluate long-term effects, while others enter a 4-week safety follow-up without treatment. Throughout the study, participants undergo regular assessments including allergen challenges to measure tolerance to specific amounts of allergen proteins at Weeks 4 and 24, depending on the sub-study. Safety is monitored by recording any adverse events up to 56 weeks. Participants are asked to avoid exposure to their allergens and complete skin prick tests, blood tests for allergen-specific IgE, and double-blind placebo-controlled food challenges. The trial duration is 52 weeks with additional follow-up for some participants.
Actively Recruiting
Researchers are evaluating the safety and effects of a study medicine called PF-07275315 for treating adults with moderate-to-severe asthma that is not well controlled. Asthma is a condition that makes breathing difficult and affects quality of life. This phase 2 clinical trial includes participants aged 18 to 75 who have had moderate-to-severe asthma for at least 12 months and have been on maintenance asthma treatment for the past 6 months. Participants will receive either PF-07275315 or a placebo, both given as multiple subcutaneous injections in the clinic over 12 weeks. The study compares experiences between those receiving the study medicine and those receiving placebo to assess safety and effects. The trial is randomized, double-blind, and placebo-controlled with parallel groups. During the study, participants will be involved for up to approximately 9.5 months depending on local regulations. They will have regular visits for injections and assessments including lung function tests like FEV1, questionnaires about asthma control and quality of life, and safety monitoring through lab tests, vital signs, and electrocardiograms. Researchers will track changes from baseline in lung function and adverse events up to 24 weeks after treatment begins.